- Record: found
- Abstract: not found
- Article: not found
A Review of Patient-Reported Outcomes Labeling for Oncology Drugs Approved by the FDA and the EMA (2012-2016)
February 2019
February 2019
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
To compare US Food and Drug Administration (FDA) and European Medicines Agency (EMA)
labeling for evidence based on patient-reported outcomes (PROs) of new oncology treatments
approved by both agencies.